

IMI 2 INFO DAY



Opportunity for Czech Entities within the 1st Call

The workshop organized by the Association of Innovative Pharmaceutical Industry (AIFP) and the Innovative Medicines Initiative IMI (joint undertaking between the European Union and the European Federation of Pharmaceutical Industries and Associations EFPIA)



6th of October 2014 at 15:00



Profesní Dům
Malostranské náměstí 25, Praha 1

The aim of the workshops:

- To introduce the topics of the current 1st IMI 2 call and to familiarize Czech scientists, R&D facilities, small and medium enterprises, hospitals and other organizations with the ways and rules of participation in the IMI 2 program.
- To support collaborative research projects and to help build networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe.



Please, RSVP by 30th September at martin.michalov@aifp.cz.



Program:



| | | |
|-------|--|---|
| 15:00 | Opening remarks | |
| | Jakub Dvořáček | Executive Director, Association of Innovative Pharmaceutical Industry (AIFP) |
| | Regina Demlová | National representative for the Czech Republic, IMI States Representative Group |
| 15:15 | IMI 2: Scientific Priorities | |
| | Magda Chlebus | Director Science Policy, EFPIA |
| 15:45 | Q&A | |
| 16:00 | The strategy for research under IMI2. Translational approaches to disease modifying therapy of Type 1 Diabetes Mellitus | |
| | Dr. Anke M. Schulte PhD | Head of Islet Biology, Diabetes Division, Sanofi Deutschland |
| 16:30 | Q&A | |
| 16:45 | Coffee break | |
| 17:00 | The strategy for research under IMI2. Discovery and validation of novel endpoints in dry age-related macular degeneration and diabetic retinopathy. | |
| | Dr. med. Elke Reissig | Global Clinical Development, Bayer Healthcare |
| 17:30 | Q&A | |
| 17:45 | IMI 2 financial and IP rules – practical advise for applicants | |
| | Magali Poinot | Legal Manager, Innovative Medicines Initiative Joint Undertaking |
| 18:15 | Q&A | |
| 18:30 | Closing Speech | |